In the context of mild persistent asthma in children aged 5-11, which of these is not part of the recommended regimen?

For children aged 5-11 with mild persistent asthma, the standard treatment guidelines recommend the use of inhaled corticosteroids (ICS) as the first-line therapy to control inflammation and reduce the frequency of asthma attacks. Cromolyn, a mast cell stabilizer, can be used as an alternative treatment option, particularly for those who may not be able to use ICS or for those who experience mild symptoms infrequently.

Theophylline, while it has been used in the past as a bronchodilator, is less commonly recommended in current practice for this age group due to its side effect profile and the need for monitoring serum levels to avoid toxicity. However, the use of long-acting beta agonists (LABA) is contraindicated as monotherapy in children with asthma, including those with mild persistent asthma, due to the risk of exacerbating asthma symptoms and the potential for increased mortality. Instead, LABAs are recommended to be used in combination with ICS for children with moderate to severe asthma who require additional control.

Thus, the use of LABA as a stand-alone treatment is not part of the recommended regimen for managing mild persistent asthma in children within this age group, making it the appropriate choice for the question posed.